U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07000682) titled 'The Clinical Study on the Treatment of SSc With UTAA91 Injection.' on May 24.
Brief Summary: This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Systemic Sclerosis (SSc)
Intervention:
BIOLOGICAL: UTAA91 injection
CAR-modified gamma delta T cells
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Wuhan Union Hospital, China
Information provided by (Respon...